STAT3 and cancer: For example, JQ1 and SAHA as co-treatments strengthened the anti-cancer efficacy of SAHA by preventing the SAHA-induced re-expression of LIFR and activation of downstream JAK1/STAT3 pathway (Zeng et al., 2016).